Supervised consumption services (SCS) are provided in legally sanctioned facilities that allow people to consume pre-obtained drugs under the supervision of trained staff and are designed to reduce the health and public order issues often associated with public drug consumption. They are also called overdose prevention centers, safe or supervised injection facilities (SIFs), and drug consumption rooms (DCRs).
Facility staff members do not directly assist in consumption or handle any drugs brought in by clients, but are present to provide sterile injection supplies, answer questions on safe injection practices, administer first aid if needed, and monitor for overdose. SCS staff also offer general medical advice and referrals to drug treatment, medical treatment, and other social support programs.
There are approximately 120 SCS currently operating in twelve countries around the world (Australia, Canada, Denmark, France, Germany, Luxembourg, the Netherlands, Norway, Spain and Switzerland) – but none in the U.S. SCSs can play a vital role as part of a larger public health approach to drug policy. They are intended to complement – not replace – existing prevention, harm reduction, and treatment interventions.
Over 100 evidence-based, peer-reviewed studies have consistently proven the positive impacts of supervised consumption services, including:
No SCS currently exist in the United States due to a host of legal and ideological barriers. SCS arguably violate various state and federal drug laws, including laws that make it illegal to use, open, or maintain property where any controlled substance is consumed.
Beyond legal obstacles (which can be overcome), there can be a lack of community support based on fears that SCS will cause an increase in drug use and crime. These fears are unfounded, however. In areas surrounding existing SCS, there has been no evidence of increased community drug use, initiation of injection drug use, or drug-related crime.
“Studies from other countries have shown that supervised injection facilities reduce the number of overdose deaths, reduce transmission rates of infectious disease, and increase the number of individuals initiating treatment for substance use disorders without increasing drug trafficking or crime in the areas where the facilities are located.” – American Medical Association
The Drug Policy Alliance has been advocating for SCS pilot programs in California, Washington, Colorado, Vermont, New York, and Maryland, among other states. San Francisco and New York City are moving forward with plans to open SCSs over the next year.
While gaining acceptance for a U.S. facility will be an uphill battle, we are committed to challenging the stigma surrounding drug use and introducing political leaders and the public to the health and societal benefits that SCSs bring to local communities.
Learn more about our efforts to establish SCS in these states: